| Biomarker ID | 914 |
| PMID | 22554381 |
| Year | 2012 |
| Biomarker | Ki-67 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated with Increasing Gleason Score |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Gleason Score ≤ 6 Vs 7 Vs ≥ 8 |
| Type of Biomarker | Prognostic |
| Cohort | 428 patients with prostate adenocarcinoma were selected and divided into two groups. The first group included 199 patients treated between January 2000 and August 2001 who were observed for biochemical recurrence. The second group included 229 patients treated between January 1982 and December 1996 who subsequently experienced biochemical recurrence and were observed for prostate cancer death. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.008 |
| Method Used | Tissue Microarray |
| Clinical | No |
| Remarks | MCM2 intensity wasn't a predictor of biochemical recurrence, but MCM2 product score (alone or with ki-67 product score) was. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | MKI67 |